203 related articles for article (PubMed ID: 9818757)
1. SCH56592 treatment of murine invasive aspergillosis.
Graybill JR; Bocanegra R; Najvar LK; Luther MF; Loebenberg D
J Antimicrob Chemother; 1998 Oct; 42(4):539-42. PubMed ID: 9818757
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304.
Defaveri J; Salazar MH; Rinaldi MG; Graybill JR
Am Rev Respir Dis; 1990 Sep; 142(3):512-5. PubMed ID: 2202244
[TBL] [Abstract][Full Text] [Related]
3. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
Manavathu EK; Cutright JL; Chandrasekar PH
Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.
Chandrasekar PH; Cutright J; Manavathu E
J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.
Martin-Vicente A; Capilla J; Guarro J
Antimicrob Agents Chemother; 2016 Jan; 60(1):296-300. PubMed ID: 26503653
[TBL] [Abstract][Full Text] [Related]
6. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Prince RA; Chi J; Kontoyiannis DP
Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
Verweij PE; Oakley KL; Morrissey J; Morrissey G; Denning DW
Antimicrob Agents Chemother; 1998 Apr; 42(4):873-8. PubMed ID: 9559799
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.
Kirkpatrick WR; McAtee RK; Fothergill AW; Loebenberg D; Rinaldi MG; Patterson TF
Antimicrob Agents Chemother; 2000 Mar; 44(3):780-2. PubMed ID: 10681359
[TBL] [Abstract][Full Text] [Related]
9. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF.
Sionov E; Mendlovic S; Segal E
J Antimicrob Chemother; 2005 Sep; 56(3):594-7. PubMed ID: 16006446
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
11. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis.
Ben-Ami R; Albert ND; Lewis RE; Kontoyiannis DP
J Infect Dis; 2013 Apr; 207(7):1066-74. PubMed ID: 23303813
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis.
Denning DW; Hall L; Jackson M; Hollis S
Antimicrob Agents Chemother; 1995 Aug; 39(8):1809-14. PubMed ID: 7486923
[TBL] [Abstract][Full Text] [Related]
13. In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone.
Manavathu EK; Dimmock JR; Vashishtha SC; Cutright J; Chandrasekar PH
J Antimicrob Chemother; 1998 Nov; 42(5):585-90. PubMed ID: 9848441
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.
Chandrasekar PH; Cutright JL; Manavathu EK
Clin Microbiol Infect; 2004 Oct; 10(10):925-8. PubMed ID: 15373889
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression.
Graybill JR; Bocanegra R; Najvar LK; Loebenberg D; Luther MF
Antimicrob Agents Chemother; 1998 Oct; 42(10):2467-73. PubMed ID: 9756743
[TBL] [Abstract][Full Text] [Related]
16. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.
Hossain MA; Maesaki S; Mitsutake K; Kakeya H; Sasaki E; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1999 Dec; 44(6):827-9. PubMed ID: 10590286
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of intravenous itraconazole against invasive pulmonary aspergillosis in neutropenic mice.
Tansho S; Abe S; Ishibashi H; Torii S; Otani H; Ono Y; Yamaguchi H
J Infect Chemother; 2006 Dec; 12(6):355-62. PubMed ID: 17235640
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.
Allendoerfer R; Loebenberg D; Rinaldi MG; Graybill JR
Antimicrob Agents Chemother; 1995 Jun; 39(6):1345-8. PubMed ID: 7574528
[TBL] [Abstract][Full Text] [Related]
19. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
20. [An experimental study of the therapeutic effect of interleukin-2 and interleukin-12 with and without amphotericin B on pulmonary fungal infection].
Zhang CR; Tang YC; Kawakami K; Zhang TT; Zhang KX; Zhu JX
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Apr; 27(4):234-6. PubMed ID: 15144612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
